ISARIC Clinical Characterisation Protocol UK (CCP-UK) - a companion study for patients with Cancer and COVID-19 (CCP-CANCER-UK)

ISARIC 临床特征协议英国 (CCP-UK) - 针对癌症和 COVID-19 患者的伴随研究 (CCP-CANCER-UK)

• 批准号: MR/V028979/1
• 负责人: Carlo Palmieri
• 金额: $ 43.95万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FV028979%2F1
• 关键词: ISARIC; Clinical; Characterisation; Protocol; UK

2019 a new virus called SARS-CoV-2 emerged, which causes a disease termed COVID-19. This is often mild but can also be severe, leading to viral pneumonia; about one in 100 infected people are expected to die of i t. However, cancer patients are likely to be at higher risk of infection and death as they have a weakened immune system as a result of either their treatment or their cancer. We will tackle many urgent questions that need answering in cancer patients to help ensure early diagnosis, that the correct shielding advice i s given, and to enable doctors and patients to make informed decisions regarding treatment during the pandemic. This will be achieved by collecting detailed data from the over 5,000 cancer patients recruited into the main UK study which has described COVID-19 (CCP-UK study). The cancer data when linked with the rich COVID-19 data will enable the following important questions to be answered:What proportion of cancer patients die from COVID-19? How does this vary based on cancer type and cancer treatment?What are the symptoms cancer patients develop with COVID-19? Does this vary based on type of cancer and treatment?What type of cancer treatments puts people at higher risk of severe illness and death?What kind of healthcare resources are needed (including intensive care) to treat COVID-19 in cancer patients?How do the outcome of patients with cancer compare with non-cancer patients taking into account age and other illnesses?

2019年，一种名为SARS-CoV-2的新病毒出现，导致一种名为COVID-19的疾病。这通常是轻微的，但也可能是严重的，导致病毒性肺炎;大约每100名感染者中就有一人预计会死于它。然而，癌症患者可能面临更高的感染和死亡风险，因为他们的免疫系统由于治疗或癌症而减弱。我们将解决癌症患者需要回答的许多紧迫问题，以帮助确保早期诊断，提供正确的防护建议，并使医生和患者能够在大流行期间就治疗做出明智的决定。这将通过收集超过5,000名癌症患者的详细数据来实现，这些患者被招募到描述COVID-19的主要英国研究（CCP-UK研究）中。当癌症数据与丰富的COVID-19数据联系起来时，将能够回答以下重要问题：死于COVID-19的癌症患者比例是多少？这是如何根据癌症类型和癌症治疗而变化的？癌症患者患上COVID-19后会出现哪些症状？这是否因癌症类型和治疗而异？什么类型的癌症治疗会使人们面临更高的严重疾病和死亡风险？需要什么样的医疗资源（包括重症监护）来治疗癌症患者的COVID-19？考虑到年龄和其他疾病，癌症患者的结果与非癌症患者相比如何？

项目成果

SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study.

• DOI: 10.3389/fimmu.2023.1146702
• 发表时间: 2023
• 期刊: Frontiers in immunology
• 影响因子: 7.3

Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis.

• DOI: 10.1001/jamanetworkopen.2022.10880
• 发表时间: 2022-05-02
• 期刊: JAMA network open
• 影响因子: 13.8